Origin in Medical Technology

Scientists Discover Origin of Malaria

... scientists reported that they have discovered the origin of malaria, one of the deadliest diseases of ... fed on a chimpanzee." Until now, malaria's origin had been unclear. Although chimpanzees were known ... malaria. "Dr. Wolfe's discovery of the origin of human malaria is a perfect example of the kind ...

Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting

... - THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose ... ID(R) molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose ... started can not be determined. Given that the origin of a cancer significantly impacts physicians' ...

FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors

... (FDA) has cleared its Pathwork(R) Tissue of origin Test for use in determining the origin of uncertain tumors. The test analyzes a tumor's ... "We believe the Pathwork Tissue of origin Test will help provide more certainty in tumor ...

Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

... Cancer Diagnosis and Identification of Tumor origin in Patients With Cancer of Unknown Primary ... Results of microRNA Signature to Identify Tissue origin Demonstrate Accuracy Exceeding 90% ... 1. "MicroRNA signature identifies tissue origin of primary and metastatic tumors"; Tuesday, June ...

Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases

... announced that its Pathwork(R) Tissue of origin Test is the focus of a study published in ... test is designed to help determine a tumor's origin so that tissue-specific management can begin. The ... and reproducibility of the Tissue of origin Test. There are an estimated 200,000 cancer ...

Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas

... had confirmed adenocarcinoma of gastrointestinal origin or of other origin if they positively expressed the RAAG12 antigen. ... cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, colorectal ...

Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

... according to their primary origin, accurate identification of the primary origin is critical for determining optimal treatment, enabling better patient outcomes. Current diagnostic methods to identify the origin of a metastasis include a range of costly, time-consuming and at times ...

Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin

... patients with ST-Elevation MI. Results are anticipated in 2009. And, the origin (Outcome Reduction with Initial Glargine Intervention) trial is currently ... disease risk factor and pre-diabetes or early type 2 diabetes. origin is a 5-year, randomized, open-label, multicenter, 2 x 2 factorial design ...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

... findings that suggested treatment with Sandostatin LAR could achieve stabilization of tumor growth in up to 50% of patients with NETs of various origin . (1) "In recent years, a growing body of evidence has suggested that Sandostatin LAR provides antitumor effects, but these are the first data ...

Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain

... for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibited analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral ...

Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium

... cancer classification assay, which provides improved cancer classification, particularly for patients diagnosed with metastatic cancer where the origin is uncertain or unknown. For more information call 1-858-587-5870 or visit http://www.bioTheranostics.com . bioTheranostics Contacts ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... type of blood clot that typically forms in a major vein of the leg, and pulmonary embolism, which occurs when a blood clot detaches from its point of origin and travels to the lungs where it becomes wedged and prevents adequate blood flow, are known collectively as venous thromboembolism. "Venous ...

Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes

... of chemotherapy. Stem cell transplants are categorized by the source of the stem cells (bone marrow, peripheral blood, or cord blood) and by their origin - autologous (from the patient) or allogeneic (from a donor). Effect of Stem Cell Source on Transplant Outcomes in Adults With Acute ...

TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System

... stenting. It can be delivered and deployed in a single step while maintaining access to the side branch and scaffolding the ostium, or the origin of the side branch. As a result, the cardiologist has greater flexibility of treatment options, with the freedom to deploy a second stent in the side ...

M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics' MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases

... era of rapidly growing effective cytotoxic and targeted therapies for known cancers, quicker and more accurate methods of identifying the tissue of origin of CUP cases would permit the use of these therapies, thereby improving the chances of achieving a response and possibly extending the patient's ...

First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval

... from adenocarcinomas that either arise in the lung or spread to the lung and pleura from other sites. Another test is designed to identify the origin of a metastasis in patients presenting with cancer of unknown primary (CUP). About microRNAs MicroRNAs (miRNAs) are recently discovered, ...

Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research

... avenue for collecting and characterizing a large enough sample set, then we can apply very sophisticated genomic research tools to understanding the origin and genetic mutations responsible for pediatric brain tumors, with the hope of uncovering new therapeutic avenues," Dr. Curran said. "Collecting and ...

Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845

... for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibits analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral ...

Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica

... from adenocarcinomas that either arise in the lung or spread to the lung and pleura from other sites. Another test is designed to identify the origin of a metastasis in patients presenting with cancer of unknown primary (CUP) origin. About microRNAs MicroRNAs (miRNAs) are recently discovered, ...

Gene Hunters Fine-Tune Marker for Common Obesity Gene

... - In Children's DNA, a Hint of a Mutation's Ancestral African origin - PHILADELPHIA, March 12 /PRNewswire-USNewswire/ -- Genomics researchers, seeking to replicate another group's discovery of an important ...

University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites

... According to the U.S. Census Bureau, the estimated number of Hispanics in the United States was 44.3 million in July 2006, making people of Hispanic origin the nation's largest and fastest-growing minority group. In 2006, the number of unique visitors to OncoLink (the English-only site) was 1,864,242, ...

St. Jude Settles Century-Old Debate on Origin of Mammalian Network of Lymphatic Vessels

... Oliver is senior author of a report on this work that appears in the October 1 issue of "Genes & Development." The St. Jude team studied the origin of the mammalian lymphatic vasculature using a powerful technique called Cre/loxP-based lineage-tracing. This technique enables researchers to label ...

Cellectar Expands Clinical Management Team

... spent over 20 years in progressively senior positions in clinical operations for pharmaceutical companies including Alcon, Amgen, Parke-Davis and origin Pharmaceuticals, Inc., a U.K.-based Clinical Research Organization (CRO), where he served as Senior Clinical Manager. Most recently, he was Clinical ...

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

... the gastrointestinal (GI) tract, the respiratory tract, the hepatobiliary (liver) system and the reproductive glands. The most common site of origin is the GI tract, with tumors often developing in the rectum, and other sections of the small intestine. Approximately 7,000 cases of carcinoid cancer ...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

... the gastrointestinal (GI) tract, the respiratory tract, the hepatobiliary (liver) system and the reproductive glands. The most common site of origin is the GI tract, with tumors often developing in the rectum, and other sections of the small intestine. Approximately 7,000 cases of carcinoid cancer ...

Myriad Genetics Presents Tumor Origin Technology at AACR

... Determining Tumor origin May Be Useful in Cancer Treatment Decisions SALT LAKE CITY, UT, April ... Hospital and the University of Pittsburgh Medical Center. Tumor origin can play an important role in choosing among treatment options for cancer ...

Study Supports Cost-Effectiveness of Medtronic's Spasticity Treatment for Children with Cerebral Palsy

... cost of the pump and the surgery to implant it. "The cost of ITB Therapy should not prevent pediatric patients with spasticity of cerebral origin from receiving this clinically effective treatment," explained Dr. Terence Edgar of the Medical College of Wisconsin's Department of Neurology and ...

Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma

... in a New Drug Application (NDA). About PTCL Peripheral T-cell lymphoma is a term which encompasses a number of different malignancies of T-cell origin that account for about 10-15% of all cases of non-Hodgkin's lymphoma. PTCL can occur at any age from young adulthood to old age and is slightly more ...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

... CTCL patients worldwide. About PTCL Peripheral T-cell lymphoma is a term which encompasses a number of different malignancies of T-cell origin that account for about 10-15% of all cases of non-Hodgkin's lymphoma. PTCL can occur at any age from young adulthood to old age and is slightly more ...

CuraGen Presents Update on Clinical Development Program for Belinostat

... paclitaxel are generally well tolerated. Two PRs (1 pancreatic and 1 rectal cancer) were noted and one patient with mixed mullerian cancer of ovarian origin achieved an 81% reduction in CA-125 levels. In addition, 11 patients achieved stable disease (SD), including one patient with bladder cancer (SD for ...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

... refers to the contraction of the heart muscle. Therapeutic vaccine: a preparation of disease-related molecules (antigens) of foreign or self origin that is capable of activating the immune system against such antigens with the goal to modulate disease processes. This foregoing press release may ...

Appendicitis: Evolving Tools to Diagnose a Classic Disease

... effects. NeutroSpec technology may also blaze the trail for in vivo tracers in other conditions such as osteomyelitis and fever of unknown origin (FUO). Meanwhile, clinicians have new options to deal with the classic yet diagnostically challenging entity of ....